NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free AMRN Stock Alerts $0.89 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.9150-Day Range$0.82▼$1.3552-Week Range$0.65▼$1.56Volume1.15 million shsAverage Volume2.19 million shsMarket Capitalization$365.82 millionP/E RatioN/ADividend YieldN/APrice Target$1.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Amarin alerts: Email Address Amarin MarketRank™ Stock AnalysisAnalyst RatingReduce1.75 Rating ScoreUpside/Downside21.6% Upside$1.08 Price TargetShort InterestBearish4.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 8 Articles This WeekInsider TradingAcquiring Shares$15,724 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.14) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.80 out of 5 starsMedical Sector843rd out of 938 stocksPharmaceutical Preparations Industry378th out of 420 stocks 1.9 Analyst's Opinion Consensus RatingAmarin has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.08, Amarin has a forecasted upside of 21.6% from its current price of $0.89.Amount of Analyst CoverageAmarin has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.43% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Amarin has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMRN. Previous Next 3.2 News and Social Media Coverage News SentimentAmarin has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Amarin this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows11 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,724.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.14) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Amarin Stock (NASDAQ:AMRN)Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More AMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMRN Stock News HeadlinesMarch 25, 2024 | finance.yahoo.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & ExpoMarch 25, 2024 | globenewswire.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 25, 2024 | americanbankingnews.comAmarin Co. plc Expected to Post Q1 2024 Earnings of ($0.04) Per Share (NASDAQ:AMRN)March 16, 2024 | finance.yahoo.comAMRN Apr 2024 3.000 callMarch 8, 2024 | finance.yahoo.comAMRN Apr 2024 1.500 putMarch 7, 2024 | finance.yahoo.comAMRN May 2024 1.000 callMarch 6, 2024 | finance.yahoo.comAMRN Mar 2024 0.500 callMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 5, 2024 | finance.yahoo.comAmarin Full Year 2023 Earnings: Beats ExpectationsMarch 2, 2024 | seekingalpha.comAmarin Corporation plc (AMRN) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comEarnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their ForecastsMarch 1, 2024 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comAmarin’s Sell Rating Affirmed Amid Declining U.S. Sales and Uncertain International ExpansionFebruary 29, 2024 | fool.comAmarin Plc (AMRN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | msn.comWhy Is Amarin Stock Trading Lower After Q4 Earnings?February 29, 2024 | finanznachrichten.deAmarin Corporation plc: Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | msn.comAmarin Non-GAAP EPS of $0.00 beats by $0.03, revenue of $74.71M beats by $3.61MFebruary 29, 2024 | finance.yahoo.comAmarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic CompetitionFebruary 29, 2024 | globenewswire.comAmarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | msn.comAmarin Q4 2023 Earnings PreviewFebruary 15, 2024 | finance.yahoo.comAmarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024February 15, 2024 | globenewswire.comAmarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024January 22, 2024 | finanznachrichten.deAmarin Corporation plc: Amarin Chairman & CEO Issue Letter to ShareholdersJanuary 22, 2024 | finance.yahoo.comAmarin Chairman & CEO Issue Letter to ShareholdersJanuary 12, 2024 | finance.yahoo.comAre Medical Stocks Lagging Amarin (AMRN) This Year?January 12, 2024 | finance.yahoo.comAre Medical Stocks Lagging Amarin (AMRN) This Year?See More Headlines Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMRN CUSIPN/A CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees275Year Founded1991Price Target and Rating Average Stock Price Target$1.08 High Stock Price Target$1.25 Low Stock Price Target$1.00 Potential Upside/Downside+21.6%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,110,000.00 Net Margins-19.26% Pretax Margin-17.49% Return on Equity-10.47% Return on Assets-6.97% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio1.80 Sales & Book Value Annual Sales$306.91 million Price / Sales1.19 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book0.66Miscellaneous Outstanding Shares410,670,000Free Float402,623,000Market Cap$365.82 million OptionableOptionable Beta2.01 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Donna PasekSenior Vice President of Human ResourcesMr. Laurent AbuafPresident of Europe & Senior VPDr. Nabil AbadirChief Medical Officer of Global Medical AffairsDr. David Keenan Ph.D.Executive VP of Technical Operations & President of EuropeKey CompetitorsUroGen PharmaNASDAQ:URGNFibroBiologicsNASDAQ:FBLGADC TherapeuticsNYSE:ADCTSilverback TherapeuticsNASDAQ:SBTXPrecigenNASDAQ:PGENView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Bought 139,988 shares on 3/1/2024Ownership: 0.135%Virtu Financial LLCBought 57,702 shares on 2/26/2024Ownership: 0.014%GSA Capital Partners LLPBought 804,370 shares on 2/16/2024Ownership: 0.210%Citadel Advisors LLCBought 18,300 shares on 2/15/2024Ownership: 0.000%GTS Securities LLCBought 14,100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AMRN Stock Analysis - Frequently Asked Questions Should I buy or sell Amarin stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" AMRN shares. View AMRN analyst ratings or view top-rated stocks. What is Amarin's stock price target for 2024? 4 brokerages have issued 1 year price targets for Amarin's stock. Their AMRN share price targets range from $1.00 to $1.25. On average, they anticipate the company's stock price to reach $1.08 in the next twelve months. This suggests a possible upside of 21.6% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts. How have AMRN shares performed in 2024? Amarin's stock was trading at $0.87 at the beginning of 2024. Since then, AMRN stock has increased by 2.4% and is now trading at $0.8908. View the best growth stocks for 2024 here. Are investors shorting Amarin? Amarin saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 18,190,000 shares, an increase of 7.1% from the February 29th total of 16,990,000 shares. Based on an average trading volume of 2,310,000 shares, the days-to-cover ratio is currently 7.9 days. View Amarin's Short Interest. When is Amarin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our AMRN earnings forecast. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. The biopharmaceutical company had revenue of $74.71 million for the quarter, compared to analysts' expectations of $72.46 million. Amarin had a negative trailing twelve-month return on equity of 10.47% and a negative net margin of 19.26%. What guidance has Amarin issued on next quarter's earnings? Amarin updated its fourth quarter 2023 earnings guidance on Wednesday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $72.0 million-$74.0 million, compared to the consensus revenue estimate of $62.0 million. What is John Thero's approval rating as Amarin's CEO? 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX). Who are Amarin's major shareholders? Amarin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include DG Capital Management LLC (1.34%), SCP Investment LP (0.62%), Hayek Kallen Investment Management (0.25%), Axxcess Wealth Management LLC (0.24%), 13D Management LLC (0.23%) and GSA Capital Partners LLP (0.21%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Amarin have any subsidiaries? The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.Read More This page (NASDAQ:AMRN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.